Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
NCT06397859
Summary
Retrospective and prospective, pharmacological, multicentre, non-profit observational study. Consecutive patients with HDV-related compensated cirrhosis starting Bulevirtide 2 mg/day from September 2019 to December 2025 will be enrolled in the study. Aim of this study is to investigate virological and clinical effectiveness of Bulevirtide 2 mg/day in patients with HDV-related compensated cirrhosis in the real-life setting. Primary endpoint of the study is the rate of virological response, defined as at least 2 Log decline or undetectable HDV RNA compared to baseline, at week 96 of treatment.
Eligibility
Inclusion Criteria: * Age≥18 years * HDV-related compensated cirrhosis defined by positivity of HDV RNA for at least 6 months and clinical or laboratory or histological diagnosis of cirrhosis * Started treatment with BLV monotherapy between September 1st 2019 and 2025 Exclusion Criteria: * Chronic hepatitis without any evidence of cirrhosis * Decompensated cirrhosis * PegIFN alpha therapy
Conditions2
Interventions1
Related trials
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide — Vir Biotechnology, Inc.
- Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD) — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D — Research Center of Periodontal-Systemic Interactions
- Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients — Karolinska University Hospital
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide — Mirum Pharmaceuticals, Inc.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06397859